uniqu approach liver diseas initi
initi coverag cnat outperform rate price target base
view compani uniqu approach liver diseas unlock signific
valu physician patient sharehold appreci cnat potenti
first-in-class oral caspas inhibitor emricasan believ could prevent
revers progress fibrosi cirrhosi develop program consist
innov clinic studi see emricasan well posit potenti
demonstr efficaci broad rang liver diseas includ nash view
emricasan program partial de-risk via partnership novarti
consid import form extern valid novel caspas mechan
look forward polt data readout
emricasan oral activ pan-caspas inhibitor suppress apoptosi
inflamm therebi reduc consequ liver insult potenti
address multipl form cirrhosi regardless origin optimist
near-term polt opportun long-term potenti nash
emricasan could use alon combin treatment base
favor profil demonstr ph studi
cnat conduct four ph clinic trial investig emricasan across
spectrum liver diseas clinic research nash focus fibrosi
earlier less sever stage diseas emricasan target fibrosi
cirrhosisa hallmark advanc diseasewith mechan potenti
diseas modif demonstr safeti patient
sever catalyst slate read next two year potenti
unlock signific valu view four clinic trial emricasan liver
diseas two fibrosi two cirrhosi use endpoint special
design measur efficaci particular patient stagger across
provid multipl opportun upsid potenti
base pedigre hepatolog portfolio potenti nash
treatment consid partnership novarti key de-risk featur
cnat regard scienc behind caspac inhibit resourc
requir success develop emricasan estim probabl
success emricasan nash peak sale
leader caspac inhibit believ cnat present uniqu
opportun investor particip potenti broadli applic
treatment liver diseas includ nash liver diseas span wide
rang sever high unmet medic need signific commerci
potenti contribut outperform rate pt cnat
biotechnolog compani focus
develop commerci
novel medicin reat liver diseas
analyst certif import disclosur see disclosur appendix
develop emricasan
nash cirrohsi compens ph de-compens
monotherapi develop novarti
bullish view cnat base compani uniqu approach
nash believ unlock signific valu physician
patient sharehold appreci cnat potenti first-in-
class oral caspas inhibitor emricasan believ could prevent
revers progress fibrosi cirrhosi patient nash
view emricasan program partial de-risk partnership
novarti consid extern valid mechan
ph post-liv transplant data polt-hcv-svr
ph nash cirrhosi data encore-ph
ph nash fibrosi data encore-nf
ph nash cirrhosi data encore-lf
develop emricasan cirrhot popul regardless
underli diseas hcv nash
competit data nash fibrosi expect
failur emricasan trial
partnership novarti fail
price target cnat base dcf valuat assum wacc residu growth rate
due patent expir expect peak sale emricasan nash reach billion ww us un-risk-adjust
market share fibrot patient cirrhot patient initi annual price us assum probabl
success nash estim ww polt hcv opportun reach un-risk adjust sale peak develop polt
hcv probabl success model approv
key downsid risk price target clinic develop risk regulatori risk emricasan current phase trial
addit risk come lower expect peak sale due higher anticip competit failur gain support
medic commun healthcar prescrib third-parti payor risk relat partnership novarti legal
challeng patent protect product
initi coverag inc cnat outperform rate
price target base view compani uniqu approach nash
meticul studi well defin patient popul provid mani shot goal
thorough understand emricasan multifactori diseas sever stage
emricasan compani lead asset develop four distinct indic
liver injuri due hepat hcv nonalcohol steatohepat nash
emricasan oral activ pan-caspas proteas inhibitor design reduc
activ human caspas enzym mediat inflamm apoptosi
nash hcv lead high level inflamm emricasan design
treat liver injuri reduc inflamm one cnat mani competit
advantag focu cirrhot patient group sever patient
studi fewer compani increasingli crowd nash space
potenti repres larg opportun due higher diagnosi rate higher unmet
medic need estim total peak nash royalti cnat un-risk-
adjust risk-adjust estim total peak polt hcv royalti
cnat un-risk-adjust risk-adjust estim
cnat finish cash fund end point
data avail four on-going emricasan trial
invest thesi cnat uniqu approach drug develop studi well-
defin patient popul provid seri catalyst thorough investig
lead asset emricasan nash multifactori diseas sever stage
view emricasan program partial de-risk via partnership
novarti consid import form extern valid
cnat conduct four clinic trial investig emricasan across wide
spectrum liver diseas clinic research nash focus
fibrosi earlier less sever stage diseas diagnosi rate far higher
cirrhot patient believ mitig typic concern among
investor regard lack diagnosi constrain nash market
larg number exist clinic trial give us confid emricasan
safeti profil target engag anti-inflammatori effect time
emricasan target uniqu differenti moa potenti achiev
number proof-of-concept readout provid signific catalyst
next two year potenti unlock signific valu view polt-
hcv data nash cirrhosi data nash
fibrosi data
cnat deliv posit clinic data see valu stock reach
month price target offer substanti upsid potenti current
price target cnat base dcf valuat methodolog
assum wacc residu growth rate due patent expir
model cnat cash balanc million debt million
expect peak sale emricasan nash reach ww us un-risk-
adjust market share fibrot patient cirrhot
patient initi annual price us assum probabl
success nash estim ww polt hcv opportun reach un-risk adjust
sale peak success develop polt hcv assum pool
hcv patient live transplant liver us base hcv treatment
landscap would receiv chronic treatment initi annual price us
assum probabl success polt hcv expect emricasan
potenti receiv regulatori approv
assum partner novarti global commerci emricasan nash upon
approv potenti combin fxr agonist tier double-digit royalti
cnat estim total peak nash royalti cnat un-risk-
adjust risk-adjust estim total peak polt hcv
royalti cnat un-risk-adjust risk-adjust
key downsid risk price target clinic develop risk regulatori risk
emricasan current phase trial addit risk come lower expect
peak sale due higher anticip competit failur gain support
medic commun healthcar prescrib third-parti payor risk
relat partnership novarti legal challeng patent protect
exhibit catalyst calendar cnat
cnat face sever major catalyst next month sever key proof-of-
concept trial emricasan read analyz four readout use
hypothet sotp analysi estim potenti up/downsid scenario
exhibit cnat binari event analysi four poc catalyst provid insight emricasan
activ could upsid next month
polt-hcv-svr ph trial encore-ph encore-nf encore-lf approvalsourc compani inform oppenheim co estimatesdrug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successsotp p-adj valu sharep-adj npv mm p-adj valu shareemricasan nash fibrosi nash cirrhosi portal hypertens nash decompens equiti share outstand use valuat cnat outperform
nearest catalyst readout polt-hcv-svr trial emricasan
post liver transplant set due hcv model opportun orphan
set post-transpl assum probabl success approv
estim trial probabl success upside/downsid
estim follow exhibit
next catalyst readout encore-ph trial emricasan
patient nash cirrhosi portal hypertens assum probabl
success approv estim probabl success trial upside/
downsid estim shown exhibit
next catalyst read-out encore-nf trial emricasan less
sever patient nash fibrosi assum probabl success
approv estim probabl success trial upside/ downsid
estim shown exhibit
final catalyst readout encore-lf trial emricasan
sever set patient nash decompens cirrhosi assum
probabl success approv estim probabl success
trial upside/downsid estim shown exhibit
exhibit binari event analysi around four read-out next two year
encore-lfencore-nfupsid cnat outperform
histori stock price ownership
cnat stock price ytd vs increas nbi
ownership predominantli hedg fund invest advisor mutual fund
insid own daili averag volum share current short interest
float day cover cnat list price
past month stock react posit partnership novarti
decemb data easl april remain flat throughout rest
possibl due lack catalyst data on-going studi
expect
meld data decompens cirrhosi patient incl nash novarti exercis optioniniti ww option collabor ema orphan drug design completeenrol encore-lf conatu inc
conatu pharmaceut inc cnat san diego ca base biopharmaceut
compani employe focus develop therapi liver diseas
caus inflamm
emricasan compani lead asset develop four distinct indic
around liver injuri due hepat hcv nonalcohol steatohepat nash
emricasan oral activ pan-caspas proteas inhibitor design reduc
activ human caspas enzym mediat inflamm apoptosi
nash hcv lead larg amount inflam emricasan design
reduc liver injuri reduc inflam cnat decid follow
tailor aproach nash liver diseas design four trial well identifi
patient popul high unmet need
nash patient decompens cirrhosi encore-lf
nash patient cirrhosi sever portal hypertent encore-ph
cnat obtain emricasan idun previous sign option
partnership exclus ww right develop commerci emricasan
decemb compani exercis may novarti partner
strong capabilit experi post-transpl market also develop
farnesoid receptor fxr agonist nash see partnership valid
go forward emricasan may develop monotherapi agent novarti may
decid develop combin anoth asset indic studi
registr trial may also evolv depend outcom well-tailor
trial cnat outlin scenario cirrhosi liver pre-and post transplant may
one path includ cirrhosi nash hcv anoth fibrosi expect
clariti data avail
emricasan current develop fibrot nash patient
sever nash patient cirrhosi and/or portal hypertens seper
polt patient due hcv model sale indic although
acknowledg registr trial may split indic differ could target
fibrot liver due nash hcv cirrhot liver pre/post transplant due
nash hcv expect peak sale emricasan nash reach billion ww
us un-risk-adjust market share fibrot patient
cirrhot patient initi annual price us assum
probabl success nash estim ww polt hcv opportun
reach un-risk-adjust sale peak develop polt hcv
assum pool hcv patient live transplant liver us base
hcv treatment landscap receiv chronic treatment initi annual price
us assum probabl success polt hcv project
emricasan potenti approv
assum partner novarti sell emricasan nash upon approv potenti
combin fxr agent assum tier low double-digit royalti cnat
estim total peak nash royalti cnat un-risk-adjust
risk-adjust estim total peak polt hcv royalti cnat
un-risk-adjust risk-adjust
estim cnat finish cash fund end
includ data four on-going trial
exhibit cnat sale estim segment
un-adjust us royalti cnatemricasan polt hcv svr emricasan nash fibrosi emricasan nash cirrhosi portal hypertens emricasan nash decompens cirrhosi un-adjust us royalti cnatemricasan polt hcv svr emricasan nash fibrosi emricasan nash cirrhosi portal hypertens emricasan nash decompens cirrhosi total emricasan royalti conatu risk un-adjust ww salesrisk-adjust ww risk un-adjust ww sale per indic risk un-adjust sale nash decompens cirrhosi risk un-adjust sale nash cirrhosi portal hypertens risk un-adjustedsal nash fibrosi risk un-adjust polt hcv sale risk -adjust ww sale per indic risk adjust sale nash decompens cirrhosi risk adjust sale nash cirrhosi portal hypertens risk adjustedsal nash fibrosi risk-adjust polt hcv sale cnat conatu pharmaceut inc
fibrosi inflamm liver diseas
emricasan oral activ pan-caspas proteas inhibitor design reduc
activ human caspas enzym mediat inflamm apoptosi
liver great regen abil compensatori growth howev
sustain sever liver injuri lead scenario gener apoptot
cell outpac bodi abil effect remov surround tissu
build-up apoptot materi lead cell death increas
inflamm disease-driven excess apoptosi result develop scar
tissu fibrosi lead tissu destruct eventu reduc capac
organ function normal
liver fibrosi excess accumul extracellular matrix protein includ
collagen occur type chronic liver diseas non-alcohol fatti
ald chronic infect hbv hcv fibrosi untreat progress cirrhosi
liver failur cancer portal hypertens often requir liver transplant
exhibit liver fibrosi predominantli caus chronic diseas hepat fibrosi
first step toward cirrhosi may lead cancer diseas associ
patient risk cirrhosi includ hcv posit patient around
us eu nafld patient us eu ald patient
billion patient histori hbv infect fraction may chronic hbv
may risk annual predict case nafld subcategori studi estim
nash patient fibrosi fb patient nash cirrhosi cr
direct annual cost per diseas us nash without fibrosi nf
nash fibrosi fb compens cirrhosi cc decompens
portal hypertens overal liver diseas area high
unmet need high diseas burden
exhibit ww burden chronic liver diseas larg alcohol liver diseas ald
hepat viru nafld lead caus cirrhosi
exhibit annual predict case nafld subcategori studi estim
nash patient fibrosi fb patient nash cirrhosi cr us
exhibit annual estim cost associ nafld
cnat focus well differenti
diseas area liver diseas space
cnat target liver diseas patient hcv post liver transplant patient
nash area high unmet need larg patient popul cnat
approach differenti player liver diseas space term
clinic develop plan drug cnat decid develop emricasan
specifi diseas popul competitor nash compani three
trial well differenti subpopul nash
nash patient cirrhosi sever portal hypertent encore-ph
nash patient decompens cirrhosi encore-lf
hepat compani focus post liver transplant popul polt
advantag approach emricasan multipl shot goal
demonstr proof-of-concept variou trial use subpopul also
allow better tailor endpoint sub-popul increas probabl
success sinc hcv nash larg patient popul select
smaller subpopul still allow larg address patient popul
subpopul data also advantag design pivot trial sinc
behavior emricasan well understood differ popul
compar larg field nash player cnat one three also focu
nash cirrhosi besid sinc diagnosi rate substanti higher
popul vs nash fibrosi see nash cirrhosi largest
opportun cnat
gilead selonsertib also studi cirrhosi report
patient drug vs placebo achiev reduct fibrosi stage w/o
worsen nash progress cirrhosi vs placebo
exhibit overview nash develop cnat use focus patient popul
multipl shot goal gain better understand drug subpopul
exhibit cnat program cover mani liver injuri popul fibrosi
post transplant polt set well defin clinic program
rational emricasan activ liver
progress liver diseas
liver diseas typic progress disease-driven excess apoptosi result
develop scar tissu fibrosi lead tissu destruct
eventu reduc capac organ function normal
progress toward fibrosi cirrhosi mediat inflamm due liver injuri
regardless underli diseas fibrosi untreat progress cirrhosi liver
failur cancer portal hypertens often requir liver transplant
companydrugmechanismstatusnashstatusdataintercept obetichol acid oca fxr regener fibrosi top-line earli revers cirrhosi initi bridg fibrosi compens stellar trial nash bridg fibrosi on-going stellar comp cirrhosi on-going top-line trial patient drug vs placebo achiev reduct fibrosi stage w/o worsen nash progress cirrhosi vs placebo progress cirrhosi vs placebo safeti genfit gnft elafibranor resolv trial on-going top-line novn tropifexor flight-fxr studi on-going enanta data safeti seladelparppar pbc onlyallegan former tobira cenicriviroc cvc immunomudul auror trial cur trial patient drug vs placebo achiv reduct fibrosi stage w/o worsen nash safeti galm glmd aramcholfatty-acid bile-acid nash ongoingfail meet endpoint hcv studi nafld top-lin ingelheimbi data expect -select top-line posit on-going complet april biopsysignific improv rel decreas liver fat mri patient treat compar placebo data mri surrogateth higher dose show statist signific reduct hepat steatosi non-invasive marker fibrosi vs placebo cnat outperform
nash fat accumul drive liver injuri healthi liver progress nafl
steatosi abnorm retent lipid within hepatocyt inflamm toward
nash balloon cell occur
hcv chronic insult viru lead apoptosi inflamm fibrosi
emricasan oral activ pan-caspas proteas inhibitor design reduc
activ human caspas enzym mediat inflamm apoptosi
studi batal et al scienc medicin activ gene injur liver
show involv gene associ inflamm tnf il etc
underscor import inflamm format fibrosi eventu
exhibit factor associ fibrosi mani involv gene tnf il etc point
inflamm one underli mechan progress
batal et al scienc medicin
anim model show caspas play central role format fibrosi
liver ca knockout mice notabl reduc nafld activ see
rational caspas inhibitor reduc fibrosi liver valid moa target
liver diseas nash
exhibit caspas well demonstr role progress fibrosi liver
see rational inhibit caspas valid
histroy compound
emricasan develop idun member senior
manag conatu idun sold compound
clinic hold due observ inflammatori infiltr mice report
fda subsequ halt develop emricasan
cnat acquir global right emricasan juli base belief
inflammatori infiltr precursor cancer lesion cnat
conduct studi show wk studi mice
inflammatori infiltr reproduc evid tumor fda
agre find lift clinic hold emricasan allow ind file
emricasan oral pan-caspas inhibitor
sever caspas cell part famili relat enzym
play import role modul critic cellular function includ function
result apoptosi inflamm seven caspas specif involv
process apoptosi three caspas specif activ pro-inflammatori cytokin
directli involv apoptosi apoptosi via caspas predominantli driven
caspas
exhibit caspas involv regul apoptosi inflamm
evid activ
preclin vitro test emricasan shown effici inhibit caspas
emricasan specif caspas famili littl activ
system date emricasan studi subject eight phase
clinic trial five phase clinic trial
cnat develop pan caspas inhibitor emricasan post transplant polt hcv
patient cirrhosi sustain virolog respons svr current trial
polt-hcv-svr trial expect read cnat receiv us orphan
design late indic underlin clinic need hcv
chronic insult viru lead cirrhosi could eventu lead liver
transplant hcv activ area develop antivir agent
agent aim clear viru underli liver damag
approxim non-transpl hcv patient fibrosi svr show
histolog sign fibrosi improv two year viru clearanc follow
transplant hcv infect reoccur transplant liver suscept
patient hcv infect us treat
diagnos varieti antivir agent achiev viral clearanc accord
cdc survey us preval hcv accord
gilead diagnos patient treat
nearli patient experi chronic symptom
chronic infect individu develop liver cirrhosi period
hcv-cirrhosi becom common indic liver transplant us
account case svr may achiev patient
histolog evid hcv recurr appar approxim transplant
recipi ensu graft failur patient fifth post-operative year
risk decompens first year cirrhosi develop transplant
patient significantli higher equival immunocompet
popul ten year overal prognosi decompens patient
especi bad one- three-year surviv respect
patient polt set hcv recurr achiev svr antivir
antivir use hcv infect start show reduct liver transplant need
cirrhot hcv patient retrospect studi eu cirrhot patient
receiv antivir therapi show week treat patient
inactiv soon week start therapi patient
delist transplant list belli et al eventu
patient delist
exhibit progress hcv
clinic develop polt hcv
cnat initi phase clinic trial polt-hcv-svr subject fibrosi
cirrhosi may modifi inclus criteria februari allow
subject incomplet cirrhosi well double-blind placebo-control clinic
trial design enrol approxim subject subject random
receiv either mg emricasan placebo oral bid month primari
endpoint exploratori proof-of-concept clinic trial chang ishak
fibrosi score compar placebo chang vs placebo
consid success trial also evalu histolog marker
biomark well safeti toler
exhibit poc emricasan program polt svr patient fibrosi data
see hcv polt trial partial derisk support two previou
trial one includ hcv patient fibrosi without fibrosi trial one
trial includ cirrhot hcv patient trial show
improv liver damag via biomark balanc activ placebo
arm trial patient hepat impair trial includ hcv patient
show suffici safeti dose higher dose studi on-going polt-
time trial also test variou dose regimen qd bid
see select dose on-going trial support
trial test emricasan bid patient safeti
efficaci emricasan test patient chronic hcv infect
unrespons antivir therapi compens liver diseas without
fibrosi patient cirrhosi hepatocellular carcinoma exclud clinic
trial primari endpoint chang alt ast week secondari endpoint
verifi activ emricasan caspas caspas assay inflamm
chang chang alt demonstr trial statist
signific emricasan treatment group compar placebo group
decreas alt seen day seven first time post-dos alt
measur decreas maintain throughout treatment period
week emricasan treatment group drug stop measur
return baselin show emricasan revers
exhibit previou indic efficaci trial hcv patient
emricasan success reduc alt ast marker liver damag
trial assess effect bid dose emricasan alt ast level
patient chronic hcv infect liver fibrosi conduct trial
end earli due observ liver infiltr discuss earlier concurr anim
studi patient trial consist screen visit two-week baselin
period three trial period separ minimum washout period two week
two-week follow-up period last treatment period patient
receiv three five possibl treatment emricasan mg placebo bid
day qd final day trial period time hold
patient complet studi reduct alt mg bid dose group
similar result mg bid dose group trial
phase ascend dose trial patient hepat impair studi
trial test emricasan patient mild moder hepat impair
sever liver diseas hcv hbv nash pbc psc day once-daili
qd bid tid dose hcv patient demonstr signific reduct
alt baselin bid dose cohort demonstr greater percentag decreas
alt level qd dose treatment emricasan complet alt level
return pre-treat level believ data support bid dose select
exhibit previou indic efficaci trial hcv patient emricasan
success reduc alt ast marker liver damag result support bid dose
phase efficaci safeti patient undergo liver transplant studi
emricasan test patient undergo liver transplant studi fail
achiev primari endpoint alt ast howev trial relev
on-going studi polt patient sinc emricasan administ
solut organ iv trial show reduct caspas activ
trial hcv patient commonli report emricasan-
treat subject headach fatigu nausea diarrhea mild
moder sever thirteen subject withdrew trial includ seven
placebo group three mg two mg one mg
emricasan group see balanc nineteen advers event report
subject consid sever greatest incid placebo mg
emricasan-tr group seven event lowest incid mg
treatment group one event sever advers event vari show pattern
across treatment group also see balanc sinc half sever
occur placebo group major advers event resolv
end trial
level emricasan treatment group similar baselin level
healthi volunt establish clinic trial see
indic normal level caspas activ remain intact
trial also includ patient renal impair show signific
opportun nash nich
cnat develop oral pan caspas inhibitor emricasan specif nash
nash patient cirrhosi sever portal hypertens encore-ph
nash patient decompens cirrhosi encore-lf
current trial expect read ph lf nf
cnat receiv fda track design nash cirrhosi underlin
nonalcohol fatti liver diseas nafld nonalcohol steatohepat nash
number one caus liver diseas countri nafld condit
defin excess fat accumul form triglycerid steatosi liver
hepatocyt histolog subgroup nafld patient liver cell injuri
inflamm addit excess fat steatohepat type nafl spectrum
condit design nash nash dramat increas risk cirrhosi
liver failur hepatocellular carcinoma nash wide consid
liver express metabol syndromediseas relat diabet mellitu type
cholesterol hypertriglyceridemia hypertens exact progress diseas
understood especi multifactori caus
three underli activ use measur nash activ liver steatosi
inflamm hepatocyt balloon inflamm one measur nash
activ target emricasan current approv endpoint nash
fibrosi improv nash resolut measur biopsi
exhibit progress nafld/nash
exhibit score nash along clinic endpoint
approxim million individu usa estim progress nash
nash-rel cirrhosi model nash patient us
potenti receiv treatment use younossi et al hepatolog templat
calcul proport nash patient fall categori nash without
fibrosi nash fibrosi nash compens cirrhosi nash
decompens cirrhosi nash portal hypertens
clinic develop nash
nash patient cirrhosi sever portal hypertens encore-ph
cnat fda fast track design cirrhosi shown reduct mean
chang hepat venou pressur hvpg surrog endpoint ph
on-going trial encore-ph random double-blind placebo-control trial
involv subject nash cirrhosi sever portal hypertens defin hvpg
mmhg determin central reader assign studi upon success
screen subject random receiv either emricasan mg bid mg bid
mg bid match placebo bid dose polt hcv
nash indic primari endpoint hvpg week secondari
endpoint improv hvpg respons use reduct baselin
caspas alt safeti top-lin data expect
exhibit trial nash patient cirrhosi sever portal hypertens
encore-ph read-out
open-label trial patient cirrhosi ph bid emricasan
day show reduct hvpg post-hoc analysi patient hvpg
mmhg enrol criteria on-going encore-ph level
marker apoptosi indic caspas activ reduc patient
patient sub cohort hvpg mmhg hvpg mmhg patient safeti
toler ok patient seriou ae assess
unrel drug common fatigu headach
see observ decreas hvpg day patient sever portal
hypertens hvpg mmhg good set-up on-going encore-ph trial
patient sever portal hypertens although post-hoc analysi
exhibit open-label data nash patient ph show hvpg reduct hvpg
patient day
nash patient decompens cirrhosi encore-lf
cnat receiv fda track design nash cirrhosi togeth
ph popul indic address subpopul decompens cirrhot
on-going encore-lf multicent double-blind random placebo-
control studi evalu safeti efficaci emricasan improv event-fre
surviv base composit clinic endpoint all-caus mortal new
decompens event meld score progress event subject
decompens nash cirrhosi least week max week studi
treatment durat least week studi visit everi week week
everi week week subject continu treatment last subject
studi reach week studi least subject random
baselin meld score top-lin data expect
exhibit trial nash patient decompens cirrhosi encore-lf
read-out
trial discuss evalu emricasan patient mild
moder hepat impair sever liver diseas hcv hbv nash pbc psc
day patient hepat impair cirrhot toler select dose
tid dose without discern subject discontinu due advers
encore-nf program explor emricasan milder nash popul without
cirrhosi compar encore-lf largest nash popul
current emricasan program term preval howev milder patient tend
lower diagnosi rate cirrhot patient on-going encore-nf trial
multicent double-blind random placebo-control trial involv subject
diagnosi definit nash fibrosi exclud cirrhosi determin
central histopathologist subject must nafld activ score na greater
score least compon na steatosi score lobular
inflamm score balloon score term fibrosi subject must
fibrosi stage limit subject stage stage use nash crn
histolog subject fibrosi stage must also diabet mellitu
metabol syndrom
upon success screen subject random receiv either emricasan
mg bid emricasan mg bid match placebo bid primari endpoint fibrosi
improv least one stage without worsen steatohepat week
accept endpoint pivot trial topline-data expect
exhibit trial nash patient without cirrhosi encore-nf read-out
estim least total includ undiagnos nash patient
unit state preval model nash without fibrosi
nash fibrosi nash compens cirrhosi
also portal hypertens nash
decompens cirrhosi base research approxim nash fibrosi
patient nash cirrhosi ph nash patient
decompens cirrhosi diagnosi undergo form treatment
emricasan current develop fibrot nash patient
sever nash patient cirrhosi and/or portal hypertens project emricasan
potenti approv assum partner novarti sell emricasan
nash upon approv potenti combin fxr agent assum tier
double-digit royalti cnat model initi net price emricasan
annual us us price eu japan respect
base drug use larg popul expect peak sale
reach nash fibrosi nash compens cirrhosi ph
nash decompens cirrhosi un-risk-adjust us cnat receiv
royalti sale assum probabl success model
us row un-risk-adjust emricasan nash royalti cnat
us row risk-adjust revenu cnat nash
hcv polt set forecast annual liver transplant rate due hcv
today number liver transplant us due hcv patient
hcv treatment declin time built model preval assum
chronic use calcul pool hcv polt patient us
eu japan time pool get smaller hcv patient popul
decreas estim transplant recipi suffer re-infect potenti
emricasan penetr popul estim treatment cost
us forecast emricasan un-risk-adjust sale polt hcv us
row cnat receiv royalti sale assum
probabl success
exhibit project emricasan revenu un-risk adjust adjust probabl
success assum partner novarti sell emricasan ww cnat receiv
exhibit project emricasan royalti monotherapi cnat un-risk adjust
adjust probabl success
total emricasan sale conatu novarti risk un-adjust us salesrisk-adjust us salesrisk un-adjust row salesrisk-adjust row risk un-adjust us sale per indicationemricasan nash decompens cirrhosi emricasan nash cirrhosi portal hypertens emricasan nash fibrosi emricasan polt hcv svr risk -adjust us sale per indicationrisk-adjust emricasan nash decompens cirrhosi risk-adjust emricasan nash cirrhosi portal hypertens risk-adjust emricasan nash fibrosi risk-adjust emricasan polt hcv svr risk un-adjust row sale per indicationemricasan nash decompens cirrhosi emricasan nash cirrhosi portal hypertens emricasan nash fibrosi emricasan polt hcv svr risk -adjust row sale per indicationrisk-adjust emricasan nash decompens cirrhosi risk-adjust emricasan nash cirrhosi portal hypertens risk-adjust emricasan nash fibrosi risk-adjust emricasan polt hcv svr total emricasan royalti conatu risk un-adjust us salesrisk-adjust us salesrisk un-adjust row salesrisk-adjust row risk un-adjust us sale per indicationemricasan nash decompens cirrhosi emricasan nash cirrhosi portal hypertens emricasan nash fibrosi emricasan polt hcv svr risk -adjust us sale per indicationemricasan nash decompens cirrhosi emricasan nash cirrhosi portal hypertens emricasan nash fibrosi emricasan polt hcv svr risk un-adjust row sale per indicationemricasan nash decompens cirrhosi emricasan nash cirrhosi portal hypertens emricasan nash fibrosi emricasan polt hcv svr risk -adjust row sale per indicationrisk-adjust emricasan nash decompens cirrhosi risk-adjust emricasan nash cirrhosi portal hypertens risk-adjust emricasan nash fibrosi risk-adjust emricasan polt hcv svr cnat outperform
cnat expect composit matter patent emricasan expir
unit state intern compani plan protect emricasan
patent direct crystallin form method use emricasan cnat
estim valid without extens model loss ip
steven mento ph presid chief execut offic
steven mento ph one cnat co-found serv presid chief
execut offic member board director sinc juli juli
decemb dr mento also serv chairman board director
dr mento year combin experi biotechnolog
pharmaceut industri dr mento presid chief execut
offic member board director idun pharmaceut inc dr mento
guid idun transit discoveri focus organ drug
develop compani multipl product near human clinic test april
idun sold pfizer inc previous dr mento serv presid chiron
viagen inc subsequ chiron technolog center gene therapi vice
presid chiron corpor dr mento vice presid
viagen prior viagen dr mento held variou posit
american cyanamid compani last posit director viral
vaccin research develop lederle-praxi biolog busi unit
american cyanamid dr mento current serv board director biocom
biotechnolog
govern bodi health section govern bodi sangamo bioscienc inc
variou academ charit organ dr mento hold ph
microbiolog rutger univers microbiolog rutger colleg
chief offic
keith marshal ph serv cnat execut vice presid chief
oper offic chief financi offic sinc august dr marshal previous
serv chief financi offic head corpor develop
torqu respons includ financ oper human
resourc corpor strategi busi develop serv manag director
advisor healthcar invest bank gca savvian
advisor provid strateg counsel healthcar compani continu
tag healthcar advisor allianc gca savvian dr
positionnameceosteven mento ph cfo cookeith marshal ph csoalfr spada ph evp clinic developmentdavid hagerti svp busin developmentdaniel ripley svp regulatori affair qualiti assuranceedward smith ph vice-president financemichel vanderti conatu inc
marshal manag director sagent advisor manag
director co-found chief financi offic montgomeri marshal
healthcar partner manag director healthcar invest bank
montgomeri co associ healthcar invest bank
jpmorgan addit respons jpmorgan partner dr
marshal previous work research associ immulog
pharmaceut corpor perform research collabor
merck around inhibit mhc class ii molecul autoimmun diseas therapi
hold concentr financ strategi entrepreneurship
univers chicago booth school busi ph pharmaceut chemistri
univers california san francisco biolog washington
univers st loui
alfr spada ph execut vice presid research develop
alfr spada ph one cnat co-found serv execut vice
presid research develop sinc februari senior vice presid
research develop sinc juli chief scientif offic sinc april
dr spada year experi pharmaceut biotechnolog
industri co-author scientif public inventor
patent dr spada vice presid
pharmaceut preclin develop idun pharmaceut
respons manag intern research develop activ idun extern
partnership includ collabor prior join idun dr
spada depart director aventi pharmaceut formerli rhone-poulenc
rorer respons medicin analyt chemistri
team work wide varieti enzyme-bas g-protein coupl
receptor gcpr target result identif clinic candid treatment
acut myocardi infarct thrombot disord coronari restenosi lipid lower
diabet cancer team discov otamixaban direct act factor xa inhibitor
reach phase clinic trial treatment acut coronari syndrom dr
spada hold chemistri worcest polytechn institut ph
chemistri massachusett institut technolog
david hagerti serv cnat execut vice presid clinic
develop sinc octob dr hagerti year experi
pharmaceut biotechnolog industri dr hagerti independ
consult clinic develop sinc april serv senior vice presid
chief medic offic ardea bioscienc previous serv
vice presid immunolog rheumatolog clinic research biogen idec
inc led clinic develop rituximab rheumatoid
arthriti lupu joint develop partner genentech previous dr hagerti
advanc sever manag role bristol-my squibb pharmaceut
research institut recent execut director
immunolog global clinic research medic lead abatacept clinic
develop program earlier career includ faculti laboratori research duti
washington univers school medicin dr hagerti serv five year
medic corp unit state navi recal activ duti oper
desert storm dr hagerti receiv degre st loui univers medicin
 degre univers notr dame board certifi intern
medicin nephrolog unit network organ share uno
certifi transplant physician
allianc manag
daniel ripley serv cnat senior vice presid busi develop
program allianc manag sinc februari previous serv vice
presid busi develop program manag sinc octob
join cnt senior director head corpor develop juli mr ripley
year integr busi develop experi initi execut
strateg busi transact emerg growth life scienc compani led
licens commerci analysi partner initi intellectu properti enforc
drive busi develop early-to-l stage product wide varieti
therapeut area technolog mr ripley serv senior director busi
develop apricu bioscienc prior
senior busi develop consult biotechnolog compani san diego
area vice presid busi develop bioblock inc
senior director head busi develop kalypsi inc
director busi develop isi pharmaceut
director busi develop immun respons
corpor inc time-frame execut multipl
licens drug discoveri collabor pharmaceut biotechnolog
compani includ oncogenex alnylam gsk sanofi alcon
mr ripley hold emphasi financ microbiolog
san diego state univers
edward smith ph senior vice presid regulatori affair
edward smith ph serv cnat senior vice presid regulatori affair
qualiti assur sinc april dr smith vice presid regulatori affair
drug safeti inc sinc octob join senior director
regulatori affair april join serv senior director
regulatori affair connet corp director regulatori affair
nektar therapeut director corpor regulatori affair valeant
pharmaceut vice presid regulatori affair research
develop radianc medic system inc previous held
research develop posit mallinckrodt inc smithklin
beecham pharmaceut ciba-geigi dr
smith held postdoctor fellowship institut pharmacolog univers
cologn germani medic univers south carolina dr smith receiv
 biolog montana state univers ph physiolog thoma
jefferson univers washington univers also hold
michel vanderti serv vice presid financ sinc march ms
vanderti serv corpor control octob march
account consult januari octob ms vanderti
year experi biotechnolog industri serv senior financi
consult role sever compani ms
vanderti held variou posit includ chief financi offic althea technolog
inc acquir ajinomoto co held posit corpor
control vical incorpor publicli trade biotechnolog compani
ms vanderti held posit corpor control
california structur real estat develop compani serv auditor
ernst young ms vanderti receiv degre
univers northern colorado
expect peak sale emricasan nash reach billion ww us un-
risk-adjust market share fibrot patient
cirrhot patient initi annual price us assum probabl
success nash estim ww polt hcv opportun reach un-risk
adjust sale peak develop polt hcv assum pool
hcv patient live transplant liver us base hcv treatment
landscap receiv chroni treatment initi annual price us
assum probabl success polt hcv project emricasan potenti
approv
assum partner novarti sell emricasan upon approv potenti
combin fxr agent assum tier double-digit royalti cnat
estim total peak nash royalti cnat un-risk-adjust
risk-adjust estim total peak polt hcv royalti cnat
un-risk-adjust risk-adjust
exhibit probability-adjust sale forecast cnat
total emricasan royalti conatu risk un-adjust ww salesrisk-adjust ww risk un-adjust ww sale per indic risk un-adjust sale nash decompens cirrhosi risk un-adjust sale nash cirrhosi portal hypertens risk un-adjustedsal nash fibrosi risk un-adjust polt hcv sale risk -adjust ww sale per indic risk adjust sale nash decompens cirrhosi risk adjust sale nash cirrhosi portal hypertens risk adjustedsal nash fibrosi risk-adjust polt hcv sale un-adjust us royalti cnatemricasan polt hcv svr emricasan nash fibrosi emricasan nash cirrhosi portal hypertens emricasan nash decompens cirrhosi un-adjust us royalti cnatemricasan polt hcv svr emricasan nash fibrosi emricasan nash cirrhosi portal hypertens emricasan nash decompens cirrhosi cnat outperform
exhibit tabl prob adjust sale royalti forecast cnat
valu cnat per share dcf assum wacc residu
growth rate due loss ip protect without extens model
ep estim respect
expect growth ep cnat cash balanc
debt
exhibit dcf valuat cnat
risk un-adjust revenu us-royalti polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi risk un-adjust us nash revenu risk un-adjust us emricasan revenu polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi risk-adjust row nash revenu risk-adjust row emricasan revenu risk un-adjust polt hcv sale risk un-adjust nash sale risk un-adjustedsal nash fibrosi risk un-adjust sale nash cirrhosi portal hypertens risk un-adjust sale nash decompens risk un-adjust emricasan sale revenu adjustmentsemricasan polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi risk-adjust polt hcv sale risk-adjust nash sale risk adjustedsal nash fibrosi risk adjust sale nash cirrhosi portal hypertens risk adjust sale nash decompens risk-adjust emricasan sale oppenheim co yeartermin valu growth valu valu per sharetermin valu growth rate conatu inc
exhibit dcf sensit analysi around prob success asset
valu per shareprob success polt hcv svrprobabl success nash cnat outperform
exhibit cnat incom statement forecast
except per share data fy probabl adj product revenues- emricasan polt-hcv- nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosis- revenu total revenues- goods- gross profit- oper expensesresearch develop adjust research develop share-bas compens d- total share-bas gener administr adjust sell gener administr share-bas compens sg a- total share-bas share-bas compens exclud non- op depreci exclud non- op other- total oper expens adjust total oper expens oper interest dividend interest incom incom comprehens incom comprehens incom incom tax expens benefit tax basic share share ep ep oppenheim co estim compani data- inc
exhibit cnat balanc sheet forecast
conatu fy asset cash invest account receivable- inventories- defer tax assets- prepaid expens current total current fix asset defer tax assets- non-curr total liabilitiescurr liabil account accru defer revenue- accru expens includ litig settlement- total current long-term portion warrant liability- long-term portion defer revenue- long-term debt- total total stockhold total liabil sourc oppenheim co compani report cnat outperform
exhibit cnat statement forecast
fy incom adjustments- depreci stock compens amort premium market loss sale assets- accru interest includ convert note payable- other- chang oper asset liabilities- account receivable- inventories- prepaid expens current defer accru account payabl flow sale purchas avail sale purchas fix assets- flow proce issuanc common stock- proceed exercis option proce issuanc convert notes- princip payment promissori note- flow effect fx- net increas decreas equival equival sourc oppenheim co compani report inc
conatu dcfdiscount analysi except per-shar data mn except per-shar data revenu growth chang work work capit valu growth valu stock oppenheim valu per sharetermin valu growth rateequ valu per shareprob success polt hcv svrprobabl success nash cnat outperform
risk un-adjust revenu book salesemricasan polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi us nash us emricasan salesemricasan polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi row nash row emricasan polt hcv nash emricasan sale adjust revenu book adjustmentsemricasan polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi salesrisk-adjust emricasan polt hcv svr emricasan nash fibrosi emricasan nash cirrhosi portal hypertens emricasan nash decompens cirrhosi risk-adjust us nash risk-adjust us emricasan salesrisk-adjust emricasan polt hcv svr emricasan nash fibrosi emricasan nash cirrhosi portal hypertens emricasan nash decompens cirrhosi risk-adjust row nash risk-adjust row emricasan risk-adjust polt hcv risk-adjust nash risk-adjust emricasan un-adjust revenu us-royalti polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi risk un-adjust us nash revenu risk un-adjust us emricasan revenu polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi risk-adjust row nash revenu risk-adjust row emricasan revenu risk un-adjust polt hcv sale risk un-adjust nash sale risk un-adjustedsal nash fibrosi risk un-adjust sale nash cirrhosi portal hypertens risk un-adjust sale nash decompens risk un-adjust emricasan sale revenu adjustmentsemricasan polt hcv svr nash fibrosi nash cirrhosi portal hypertens nash decompens cirrhosi risk-adjust polt hcv sale risk-adjust nash sale risk adjustedsal nash fibrosi risk adjust sale nash cirrhosi portal hypertens risk adjust sale nash decompens risk-adjust emricasan sale oppenheim co estim conatu pharmaceut inc
probabl success
emricasan nash fibrosi
probabl success
emricasan nash cirrhosi portal hypertens
probabl success
emricasan nash decompens cirrhosi
probabl success
collabor revenu mileston
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op
depreci exclud non-gaap op ex
interest dividend incom
stock price compani mention report
